TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Pemetrexed and Cisplatin as Treatment in Small Cell Lung Cancer

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Histologic or cytologic diagnosis of Small Cell Lung Cancer (SCLC).~* Functional stage from 0 to 2 of the ECOG functional scale~* No previous systemic chemotherapy, immunotherapy or biologic therapy for SCLC.~* Previous bone marrow radiotherapy less than 25% is allowed.~* There must be at least one measurable lesion that complies with the solid tumor response evaluation criteria.~* Appropriate organic function.~* Life expectancy estimated at 12 weeks minimum.~* Females must be surgically sterile, postmenopausal or follow approved medical contraceptive methods during the treatment period and 6 months afterwards. Males must be surgically sterile or use a contraceptive method during the treatment period and during 6 months after treatment.~* The patient must be compliant and located close to the trial area for appropriate follow-up.~* The patient or his/her legal representative must sign an informed consent document.~* Patients must be at least 18 years of age.~Exclusion Criteria:~* Having received treatment for the last 30 days with a drug that has not obtained regulatory approval.~* Having participated in a previous pemetrexed trial.~* Mixed histologic diagnosis of SCLC and NSCLC.~* Concurrent illness.~* Having an active infection.~* Severe cardiac disease.~* Having received recently or concurrently a vaccine against yellow fever.~* Having suffered a previous malignant process other than SCLC.~* Central nervous system (CNS) metastases require concurrent corticoid therapy. Treated and stable CNS metastases are allowed.~* Clinically relevant fluid accumulation in the third space.~* Significant weight loss (greater than or equal to 10%) within 6 weeks prior to trial inclusion.~* Concurrent administration of any other anti-tumor treatment.~* Severe renal failure.~* Unable to discontinue administration of non-steroidal anti-inflammatory (NSAIDS) agents.~* Inability or unwillingness to take folic acid and vitamin B12 supplements.~* Inability to take corticoids.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- A (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Study for Treatment With TH-4000 (Tarloxotinib) in Epidermal Growth Factor Receptor (EGFR) Mutant, T790M-negative Non-small Cell Lung Cancer (NSCLC) Patients

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Key Eligibility Criteria:~* Eastern Cooperative Oncology Group (ECOG) performance status 0-1~* Confirmed recurrent Stage IV NSCLC which progressed while on treatment with EGFR TKI~* Measurable disease according to Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1)~* Documented evidence of an EGFR mutation known to be associated with an EGFR TKI sensitivity~* No T790M mutation or small cell transformation including an assessment from tumor biopsy obtained while on or subsequent to the most recent EGFR TKI therapy~* Acceptable laboratory results as indicated by protocol~* Acceptable cardiac function as indicated by protocol~Key Exclusion Criteria:~* Receiving medication that prolongs QT interval, with a risk of causing Torsades de Pointes (TdP) unless ECG meets inclusion criteria while on a stable dose of the medication~* Family history of long corrected QT interval (QTc) syndrome~* Symptomatic central nervous system (CNS) lesions~* Radiation therapy within 2 weeks prior to the first dose of study medication~* Major surgery within 4 weeks or minor surgery within 2 weeks prior to the first dose of study medication~* Concurrent active malignancy requiring systemic treatment~* Any other serious uncontrolled medical disorders or psychological conditions that may interfere with study conduct including but not limited to: clinically significant active infection (e.g., tuberculosis, viral hepatitis, human immunodeficiency virus \[HIV\]), recent (within 6 months) myocardial infarction or unstable angina, congestive heart failure, poorly-controlled hypertension or diabetes, concurrent active malignancy, or psychiatric condition that may interfere with the patient's ability to follow study procedures~* Pregnant or breast-feeding

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- TH-4000 (Tarloxotinib) (Type: EXPERIMENTAL): TH-4000 (Tarloxotinib), 150 mg/m2 will be administered by IV infusion on Days 1, 8, 15, and 22 of each 28-day cycle until progressive disease (PD) or unacceptable toxicity

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Weight & Insulin Sensitivity on Reproductive Function in PCOS: Studies in Skeletal Muscle & Adipose

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Enrolled in PULSE NCT01482286~Exclusion Criteria:~* Withdraw from PULSE NCT01482286

- Gender: FEMALE
- Minimum Age: 20 Years
- Maximum Age: 40 Years
- Healthy Volunteers: f

Study Arms:
- Polycystic Ovary Syndrome (Type: None): Overweight women with polycystic ovary syndrome. 20 - 40 years, inclusiveBody mass index ≥ 25kg/m2History of irregular menstrual cycles (fewer than 8 regular cycles in the past year)Clinical and/or biochemical androgen excess (Free androgen index\>3.85 and/or hirsuitism rating ≥8)Anovulatory menstrual cycles (determined during screening)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Clinical Value of Left Atrial Appendage Flow for Prediction of Successful Catheter Ablation for Persistent Atrial Fibrillation

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* First-time radiofrequency catheter ablation for pAF. pAF was defined as continuous AF lasting longer than 1 month, resistant to either electrical or pharmacological cardioversion.~* Informed consent~Exclusion Criteria:~* Severe valvular disease requiring surgery~* Valvular prosthesis~* Known severe coronary artery disease~* Atrial and/or ventricular thrombosis~* New York Heart Association functional class III to IV~* Cerebrovascular disease~* Pulmonary embolism~* Latent or manifest hyperthyroidism

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: None

Study Arms:
- patients with persistent atrial fibrillation ablation (Type: None): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: safety issues
Please assess the completion status of the following clinical trial:

Trial Title: Vaginal Estrogen for the Treatment of Faecal Incontinence in Women

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Post menopausal women with faecal incontinence~Exclusion Criteria:~* No hormone replacement therapy (HRT) for at least 8 weeks prior to screening~* Diabetes mellitus~* Neurological disorder~* Terminal illness~* Current treatment for breast cancer~* Unable to give informed consent

- Gender: FEMALE
- Minimum Age: 45 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Practice Patterns Among Gynecologic Oncologists on Tumor Genetic Testing in Endometrial Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: OTHER
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Member of the Society of Gynecologic Oncology~* Gynecologic Oncologist or Gynecologic Oncology Fellow-in-Training

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Gynecologic Oncologists (Type: None): Gynecologic Oncologists and gynecologic oncology fellows-in-training from around the world, who are members of the Society of Gynecologic Oncology (SGO).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: A Study Designed to Evaluate ODSH in Subjects With Exacerbations of COPD

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. Male and female patients (40 years of age or older) with an established diagnosis of COPD based upon medical history who are being admitted to the hospital to treat an exacerbation of COPD;~2. Normal prothrombin time and activated partial thromboplastin time; Platelet count; hemoglobin and hematocrit~Exclusion Criteria:~1. Certain diseases such as:~   * asthma;~  * left heart failure or pulmonary embolism;~  * lung cancer;~  * pneumonia~  * liver or kidney disease~  * blood clotting disorder~  * Positive HIV or hepatitis tests~  * GI bleeding, physical trauma with bleeding, any disease with bleeding within 60 days of study entry~2. Certain medications such as:~   * Plavix®~  * Warfarin~  * Heparin therapy~  * Certain antibiotics~3. Exacerbations that are too severe (requiring intubation and mechanical ventilation)~4. Women of child-bearing potential, pregnancy or breast-feeding~5. Unable or unwilling to provide informed consent and follow study procedures.

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Open Label (Type: EXPERIMENTAL): Initial six subjects treated with ODSH open-label to confirm safety in subjects with an acute exacerbation of COPD; six additional patients will be enrolled following safety review.
- 0.9% Sodium Chloride (Type: PLACEBO_COMPARATOR): Placebo Comparator: Placebo-Control Arm 0.9% Sodium Chloride Solution bolus; dose of 0.375mg/kg/hr over 96 hours.
- Randomized, Blinded, ODSH Arm (Type: ACTIVE_COMPARATOR): Subjects will receive standard of care treatment. ODSH is administered in bolus doses estimated to inhibit inflammatory mediators randomized 1:1 to ODSH 8mg/kg or placebo. The continuous infusion dose will be 0.375 mg/kg/hr over 96 hours.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Reduced Intensity AlloTransplant For Osteopetrosis

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients eligible for transplantation under this protocol will be \<45 years of age, and will be diagnosed with severe osteopetrosis. This will be defined as having the following manifestations of the disease.~* Bones that are uniformly markedly dense based on skeletal survey~* No history that would suggest autosomal dominant inheritance~* Evidence of hematologic changes that are attributed to the underlying disease, including the need for ongoing transfusions, OR~* the presence of progressive anemia or thrombocytopenia, OR a white blood cell differential with a predominance of immature forms and evidence of extramedullary hematopoiesis, OR~* persistence of serious infectious complications that are thought to be due to the abnormal architecture of the bone that are resistant to surgical and medical interventions.~Exclusion Criteria:~* Patients \>45 years of age~* Evidence of hepatic failure~* pulmonary dysfunction sufficient to substantially increase the risk of transplant~* Renal dysfunction with glomerular filtration rate (GFR) \<30% of predicted.~* Cardiac compromise sufficient to substantially increase the risk of transplantation~* Severe, stable neurologic impairment.~* Human immunodeficiency virus (HIV) positivity.~* Pregnant or lactating females

- Gender: ALL
- Minimum Age: None
- Maximum Age: 45 Years
- Healthy Volunteers: f

Study Arms:
- Intent-To-Treat (Type: EXPERIMENTAL): Patients enrolled and received study treatment.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: safety issues
Please assess the completion status of the following clinical trial:

Trial Title: Antineoplaston Therapy in Treating Patients With Cancer of Unknown Primary Origin

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically confirmed adenocarcinoma of unknown primary that is unlikely to respond to existing therapy, including surgery, radiotherapy, and chemotherapy~  * Evidence of tumor by MRI, CT scan, chest x-ray, or radionuclide scan~PATIENT CHARACTERISTICS:~Age:~* 6 months and over~Performance status:~* Karnofsky 60-100%~Life expectancy:~* At least 2 months~Hematopoietic:~* WBC at least 2,000/mm\^3~* Platelet count at least 50,000/mm\^3~Hepatic:~* No hepatic insufficiency~* Bilirubin no greater than 2.5 mg/dL~* SGOT and SGPT no greater than 5 times upper limit of normal~Renal:~* No renal insufficiency~* Creatinine no greater than 2.5 mg/dL~* No history of renal conditions that contraindicate high dosages of sodium~Cardiovascular:~* No uncontrolled hypertension~* No history of congestive heart failure~* No history of other cardiovascular conditions that contraindicate high dosages of sodium~Pulmonary:~* No severe lung disease, such as chronic obstructive pulmonary disease~Other:~* Not pregnant or nursing~* Fertile patients must use effective contraception during and for 4 weeks after study participation~* No active infection~* No nonmalignant systemic disease~* Not a high medical or psychiatric risk~PRIOR CONCURRENT THERAPY:~Biologic therapy:~* At least 4 weeks since prior immunotherapy~* No concurrent immunomodulating agents~Chemotherapy:~* At least 4 weeks since prior chemotherapy (6 weeks for nitrosoureas)~Endocrine therapy:~* Concurrent corticosteroids allowed~Radiotherapy:~* At least 8 weeks since prior radiotherapy~Surgery:~* Recovered from prior surgery~Other:~* Prior cytodifferentiating agents allowed~* No prior antineoplastons~* No other concurrent antineoplastic agents

- Gender: ALL
- Minimum Age: 6 Months
- Maximum Age: 99 Years
- Healthy Volunteers: f

Study Arms:
- Antineoplaston therapy (Type: EXPERIMENTAL): Antineoplaston therapy (Atengenal + Astugenal) by IV infusion every four hours for at least 12 months. Study subjects receive increasing dosages of Atengenal and Astugenal until the maximum tolerated dose is reached.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Positron Emission Tomography - Computed Tomography (PET-CT) Cetuximab Project

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Histologically or cytologically proven colorectal cancer~* Unresectable stage IV disease~* K-Ras wild type tumour~* Patients scheduled to undergo chemotherapy with irinotecan and cetuximab~Exclusion Criteria:~* Prior abdominal/pelvic radiotherapy, surgery or chemotherapy within 3 months prior to inclusion in the study~* Poorly controlled diabetes~* Concomitant serious illness, such as uncontrolled angina pectoris, myocardial infarction, heart failure, uncontrolled hypertension, infection~* Symptomatic brain metastases~* Pregnancy or participants of reproductive potential who are sexually active and not willing/able to use medically appropriate contraception

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- PET-CT (Type: None): Patients with Unresectable stage IV colorectal cancer; eligible for 3rd line Irinotecan and Cetuximab

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: HFNC Effect on BCSS in Patients With COPD

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~One previous chronic obstructive pulmonary disease exacerbation in last year.~Exclusion Criteria:~Can not be oxygen dependant PaCO2 \< 60

- Gender: ALL
- Minimum Age: 35 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- High Flow Nasal Cannula Participants (Type: EXPERIMENTAL): High Flow Nasal Cannula Participants will be their own control, they will be in study for 3 months prior to receiving equipment and then will be studied for 3 additional months on study.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Ex Vivo Pilot Study of the Impact of Nasal Breathing During the Administration of Inhaled Corticosteroids by Inhalation Chamber in Asthmatic Children Ages Between 1 and 4-year-old

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Aged from 1 to 4 years old~* Male or female~* With medically diagnosed asthma~* Patients who are used to use an inhalation chamber with a face mask~* Patients who have not had asthmatic decompensation for at least 1 month.~* Patients' parents having given their written consent~* With normal clinical respiratory examination on the day of the test.~Exclusion Criteria:~* Patients whose parents are unable to understand the purpose and conditions of the study~* Patients whose parents are unable to give their consent~* Patients participating in another clinical trial or exclusion period from a previous clinical trial~* Patients presenting with a nasopharyngeal infection in the previous month~* Child with nasal obstruction, nocturnal snoring, adenoid facies or facial malformation~* Patient presenting with an asthmatic decompensation episode in the previous month

- Gender: ALL
- Minimum Age: 1 Year
- Maximum Age: 4 Years
- Healthy Volunteers: f

Study Arms:
- Flixotide (Type: EXPERIMENTAL): Patients inhale first Flixotide and then Qvar
- Qvar (Type: EXPERIMENTAL): Patients inhale first Qvar and then Flixotide

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Improving SWAllowing After Stroke With Transcranial Direct Current Stimulation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~- acute stroke (ischemic / hemorrhagic) with dysphagia~Exclusion Criteria:~* major swallowing impairment before the stroke~* troubles of comprehension impairing communication~* major cognitive dysfunction, neuro-degenerative disease, or major psychiatric condition (e.g. depression, Alzheimer's disease, ...)~* very unstable health issue (e.g. severe cardiac dyscfct, end-stage renal failure, unstable diabetes, ...)~* intracranial metal and/or devices excluding tDCS application~* chronic intake of major drugs modifying brain activity (e.g. AEDs, antipsychotics)~* regular use of alcohol or recreative drugs~* epilepsy~* pregnancy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: t

Study Arms:
- real tDCS (Type: ACTIVE_COMPARATOR): patients will receive non-invasive and painless brain stimulation over the rain areas involved in swallowing.~tDCS will be applied during swallowing therapy, during 20 minutes
- sham tDCS (Type: PLACEBO_COMPARATOR): this will be exactly as for real tDCS unless that the tDCS will be rapidly turned off, unbeknown from patients-therapist-examinator (double-blind trial)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues